Discovery of this unique GoF property, conferred by the CaM-F142L mutation, may potentially serve as a molecular guide for how to manipulate CaM-dependent RyR2 inhibition as a therapeutic strategy for treating arrhythmias and/or heart failure. The gene discussed is CALM1; the disease is Arrhythmia.